Abstracts tagged "giant cell arteritis"

Abstract Number: 1619 • ACR Convergence 2025
Systemic Immune-Inflammation Index Is Superior to Neutrophil-to-Lymphocyte Ratio for Assessing Disease Activity in Polymyalgia Rheumatica and Giant Cell Arteritis
Gaston Ariel Ghio¹, Maria Gabriela Paz Machado², Evelin Encalada², Imma Perez Nadales², Georgina Salvador Alarcón², Elena Riera Alonso², manel pujol², Marta Pujol Teixidor² and Silvia Martinez Pardo², ¹Hospital Universitari Mùtua Terrassa, Terrassa, Catalonia, Spain, ²Hospital Universitari Mùtua Terrassa, Terrassa, Spain
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are chronic inflammatory disorders predominantly affecting patients over 50. Despite unclear etiopathogenesis, both conditions share central…
Abstract Number: 0762 • ACR Convergence 2025
Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers
Verena Schoenau¹, Giulia Corte², Koray Tascilar³, Fabian Hartmann², Sebastian Ott², Wolfgang Schmidt⁴, Andreas Krause⁵, Pfeil Alexander⁶, Peter Oelzner⁶, Marc Schmalzing⁷, Matthias Fröhlich⁸, Michael Gernert⁸, Jörg Henes⁹, Nils Venhoff¹⁰, Bernhard Hellmich¹¹, Bernhard Manger², Georg Schett¹² and Juergen Rech¹², ¹- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ²- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁶Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, ⁷Department of Medicine II, Rheumatology/ Immunology,University Hospital of Wuerzburg, Wuerzburg, Bayern, Germany, ⁸University Hospital of Wuerzburg, Department of Medicine II, Rheumatology/ Immunology, Wuerzburg, Germany, ⁹Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ¹⁰University of Freiburg, Freiburg, Germany, ¹¹Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ¹²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: The diagnosis and management of giant cell arteritis (GCA) has significantly evolved over the last decades, mainly due to advances in imaging techniques and…
Abstract Number: 0746 • ACR Convergence 2025
Impact of Frailty on Mortality in GCA and PMR: A Retrospective Cohort
Fatima Hassan¹, Michael Putman² and Sebastian E Sattui³, ¹Medical College of Wisconsin, Menomonee Falls, WI, ²The Medical College of Wisconsin, Milwaukee, WI, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Frailty, a syndrome associated with decreased physiologic reserve, is associated with adverse outcomes. The prevalence and impact of baseline frailty on the risk of…
Abstract Number: 1617 • ACR Convergence 2025
Evaluating Familiarity and Knowledge Gaps in Polymyalgia Rheumatica Among Public Health Professionals
Erik Stone¹, Shilpa Venkatachalam², angela Degrassi³, Laura Stradford¹, Ambika Vartak⁴ and Shelley Fritz⁵, ¹Global Healthy Living Foundation, Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Meriden, ⁵Global Healthy Living Foundation, Kalaheo, HI
Background/Purpose: Polymyalgia rheumatica (PMR) is a commonly occurring inflammatory condition affecting older adults, primarily presenting with bilateral shoulder and hip stiffness. Despite its high prevalence…
Abstract Number: 0763 • ACR Convergence 2025
Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience
wendy Perdomo, Sean Welch and Timothy Wilson, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Giant cell arteritis (GCA) is predominantly large vessel vasculitis that has a specific prediliction for vasculature of the head, eyes and jaw and if…
Abstract Number: 0745 • ACR Convergence 2025
Prevalence and Clinical Significance of Low ESR and CRP in Giant Cell Arteritis: A Population Based Study
Eugenio de Miguel, Natalia López-Juanes, Maria-Eugenia Miranda-Carus, Carlota Ureta, Chamaida Plasencia-Rodríguez and Irene Monjo Henry, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Traditionally, elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) had been considered a hallmark of GCA and both are included in the 2022…
Abstract Number: 1616 • ACR Convergence 2025
Short-Course Prednisone and Methotrexate in Polymyalgia Rheumatica: A Potential Therapeutic Approach
Edoardo Conticini¹, Silvia Grazzini¹, Raffaele Truscelli², Paolo Falsetti³, Luca Cantarini⁴ and Bruno Frediani⁴, ¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Italy, Siena, Italy, ²University of Siena, Siena, Italy, ³Siena University Hospital, Siena, Italy, ⁴Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University Hospital of Siena, Siena, Italy, Siena, Italy
Background/Purpose: Despite being considered an easy-to-diagnose and easy-to-treat condition, the optimal treatment of PMR is far from being fully elucidated. Three recently published trials have…
Abstract Number: 0761 • ACR Convergence 2025
Fast-Track Clinics Improve Visual Outcomes in Giant Cell Arteritis: A Meta-Analysis
Tiago Beirão¹, Catarina Rua¹, Catarina Silva¹, Mariana Patela¹, Romana Vieira¹, Joana Abelha-aleixo¹, Patrícia Pinto¹, Flávio Costa¹, Ana Sofia Pinto¹, Diogo Fonseca¹, Tiago Meirinhos¹, Ajexandro Souto² and Taciana Videira¹, ¹Unidade Local de Saude Gaia e Espinho, Porto, Portugal, ²Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
Background/Purpose: Giant Cell Arteritis (GCA) is a chronic, inflammatory condition, primary affecting the medium and larger arteries, usually in patients older than 50 years. It…
Abstract Number: 0744 • ACR Convergence 2025
Age and Sex Influence on Clinical Manifestations of Giant Cell Arteritis: Results from the ARTESER Registry
Delia Fernandez-Lozano¹, Marta Domínguez-Álvaro², Javier Narváez³, Noemí Garrido⁴, Eugenio de Miguel⁵, Paula Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maite Silva-Diaz⁸, Joaquín M Belzunegui⁹, Clara Moriano¹⁰, Julio Sánchez Martín¹¹, Itziar Calvo-Zorrilla¹², Vicente Aldasoro Cáceres¹³, lydia Abasolo Alcazar¹⁴, Javier Loricera¹⁵, rafeal Benito-Melero¹⁶, Maria Garcia-Villanueva¹⁷, Fernando Sánchez-Alonso², Santos Castañeda¹⁸, José L. Hernández¹⁹ and Ricardo Blanco²⁰, ¹Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complexo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain, ⁹Hospital Universitario Donostia, San Sebastian, Spain, ¹⁰Hospital León, LEON, Castilla y Leon, Spain, ¹¹Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹²Galdakao-Usansolo University Hospital, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴IdISSC. HCSC, Madrid, Madrid, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹⁶MD, barcelona, Spain, ¹⁷Hospital Ramón y Cajal, Madrid, Spain, ¹⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹⁹Instituto de Investigación Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis that predominantly affects older adults, with a higher prevalence in women. Previous studies exploring sex-related…
Abstract Number: 2704 • ACR Convergence 2025
Complete metabolic response on PET/CT in giant-cell arteritis-related large vessel vasculitis : comparison of two strategies using glucocorticoids or glucocorticoids + tocilizumab
Hubert De Boysson¹, Anael Dumont², Thibault Orvain², Olivier Espitia³, Cloé Comarmond⁴, Samuel Deshayes⁵, Laurent Sailler⁶, Jean-François Alexandra⁷, Maxime Samson⁸ and Achille Aouba⁵, ¹Internal Medicine, CHU Caean, Caen, France, ²Caen University Hospital, Caen, Basse-Normandie, France, ³CHU de Nantes, Nantes, France, ⁴Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ⁵Caen University Hospital, Caen, France, ⁶CHU Toulouse, Toulouse, France, ⁷Internal Medicine, Hôpital Bichat, APHP, Paris, France, ⁸CHU Dijon Bourgogne, Dijon, France
Background/Purpose: Persistent large-vessel vasculitis (LVV) on PET/CT in giant-cell arteritis (GCA) is associated with a higher risk of aortic dilation. Few data are available on…
Abstract Number: 1614 • ACR Convergence 2025
A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
Alice Bartoletti¹, Georgina Ducker², Mrinalini Dey³, Durga Prasanna Misra⁴, Sara Monti⁵, Bernhard Hellmich⁶, Chetan Mukhtyar⁷, Paul Studenic⁸ and Elena Nikiphorou⁹, ¹Department of Rheumatology, ASST Gaetano Pini CTO, Milan, Italy, Milan, Lombardia, Italy, ²Department of Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, UK, Norwich, England, United Kingdom, ³Department of Rheumatology, King's College Hospital NHS Foundation Trust, London, UK, London, England, United Kingdom, ⁴Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, Lucknow, Uttar Pradesh, India, ⁵University of Pavia, Pavia, Pavia, Italy, ⁶Department of Internal Medicine, Rheumatology, Pulmonology, Nephrology and Diabetology, Medius Kliniken Kirchheim/Teck, University Tübingen, Tübingen, Germany, Kirchheim-Teck, Germany, ⁷Norfolk and Norwich University Hospital, Norwich, England, United Kingdom, ⁸Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁹King's College London, London, United Kingdom
Background/Purpose: European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of Polymyalgia Rheumatica (PMR) and Large Vessel Vasculitis (LVV) date back to 2015…
Abstract Number: 0760 • ACR Convergence 2025
The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Sema Kaymaz-Tahra¹, Cansu Arslantürk Güneysu², Sinem Nihal Esatoglu³, Güllü Sandal Uzun⁴, Burak Ince⁵, Mete Kara⁶ and Gulen Hatemi³, ¹Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, ²Sakarya Training and Research Hospital, Division of Rheumatology, Sakarya, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Hacettepe University, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁵Istanbul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, ⁶Izmir City Hospital, Division of Rheumatology, Izmir
Background/Purpose: To assess the sustained remission rates of the targeted therapies in 52th week in patients with giant cell arteritis (GCA).Methods: We performed a systematic…
Abstract Number: 0743 • ACR Convergence 2025
Giant Cell Arteritis Relapse After Treatment with Two Months of Prednisone and 12 Months of Tocilizumab
David O'Dea¹, Guy Katz¹, Belen Arevalo Molina¹, Adam Jarvie², Mark Matza¹, Ana Fernandes¹, John Stone³ and Sebastian H Unizony⁴, ¹Massachusetts General Hospital, Boston, MA, ²Emory University School of Medicine, Atlanta, GA, ³Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The optimal duration of tocilizumab (TCZ) treatment for giant cell arteritis (GCA) is unclear. Observational studies have shown that 50-60% of patients relapse after…
Abstract Number: 2703 • ACR Convergence 2025
Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
Ruoheng Zeng¹, Ryan Rebello², Konstanze Guggenberger³, Joshua Baker⁴, Shubhasree Banerjee⁴, Robert Kurtz⁴, Naomi Amudala⁴, Peter Merkel⁴ and Rennie Rhee⁴, ¹University of Pennsylvania School of Medicine, Philadelphia, PA, ²St. Joseph’s Hospital at McMaster University, Hamilton, ON, Canada, ³University Hospital of Wuerzburg, Wuerzburg, Germany, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is a need for better tools to monitor disease activity in giant cell arteritis (GCA). Prior studies demonstrated that vascular enhancement on cranial…
Abstract Number: 1175 • ACR Convergence 2025
Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
Nils Venhoff¹, Wolfgang Schmidt², Raoul Bergner³, Juergen Rech⁴, Leonore Unger⁵, Stephanie Finzel⁶, Ioana Andreica⁷, David Kofler⁸, Stefan Weiner⁹, Prof. Dr. med. Peter Lamprecht¹⁰, Hendrik Schulze-Koops¹¹, Meryl Mendelson¹², Weibin Bao¹³, Monica Keyport¹⁴, Meron Maricos¹⁵, Valeria Jordan M.¹⁶ and Jens Thiel¹⁷, ¹University of Freiburg, Freiburg, Germany, ²Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ³Department of Internal Medicine A, Nephrology and Rheumatology, Municipal Hospital Ludwigshafen, Ludwigshafen, Germany, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁵Städtisches Klinikum Dresden, Dresden, Germany, ⁶Universitétsklinikum Freiburg, Freiburg im Breisgau, Germany, ⁷Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany, ⁸University of Cologne, Cologne, Germany, ⁹Brüderkrankenhaus Trier, Trier, Germany, ¹⁰University of Lübeck, Lübeck, Germany, ¹¹LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany, ¹²Novartis Pharmaceuticals, Larchmont, NY, ¹³Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁴Novartis Pharmaceuticals, Stillwater, MN, ¹⁵Novartis, Nürnberg, Germany, ¹⁶Novartis Pharmaceuticals Corporation, Tenafly, NJ, ¹⁷University Hospital Freiburg, Medical University Graz, Freiburg, Germany
Background/Purpose: GCA and PMR are closely related, immune-mediated chronic inflammatory diseases often occurring concurrently in individuals over 50.1,2 While glucocorticoids (GC) are the mainstay of…

1
2
3
…
36
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].